Mycophenolate for the Treatment of Primary Sjögren's Syndrome

Overview

Journal J Transl Int Med

Publisher Sciendo

Specialty General Medicine

Date 2020 Oct 16

PMID 33062590

Citations 3

Authors

Weiqian Chen

Jin Lin

Affiliations

Soon will be listed here.

Abstract

Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease with exocrine gland dysfunction and multi-organ involvement. Currently, there is an increasing trend toward non-steroid therapy for the treatment of autoimmune diseases. Some biological agents or immunosuppressive drugs may be the ideal choices. In real-world practice, as patients have severe systemic complications or organ damage, they will have a bad prognosis even if they are treated with high-dose steroids and strong immunosuppressive drugs. However, if we can start early intervention and prevent progressive development in advance, the patient may have a good prognosis. Mycophenolate is an immunosuppressive drug with minor side effects. Here, we conduct a systemic review and find supporting evidence that patients with pSS benefit from early mycophenolate therapy. Mycophenolate may be the first-line treatment for pSS patients in the future.

Citing Articles

Defining the Role of Monocytes in Sjögren's Syndrome.

Sequi-Sabater J, Beretta L Int J Mol Sci. 2022; 23(21).

PMID: 36361554 PMC: 9654893. DOI: 10.3390/ijms232112765.

Current status of xenotransplantation research and the strategies for preventing xenograft rejection.

Zhou Q, Li T, Wang K, Zhang Q, Geng Z, Deng S Front Immunol. 2022; 13:928173.

PMID: 35967435 PMC: 9367636. DOI: 10.3389/fimmu.2022.928173.

Mycophenolate for the Treatment of Primary Sjögren's Syndrome.

Chen W, Lin J J Transl Int Med. 2020; 8(3):146-149.

PMID: 33062590 PMC: 7534498. DOI: 10.2478/jtim-2020-0023.

References

Schnabel A, Reuter M, Gross W . Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum. 1998; 41(7):1215-20. DOI: 10.1002/1529-0131(199807)41:7<1215::AID-ART11>3.0.CO;2-Y. View

Chen W, Lin J . Mycophenolate for the Treatment of Primary Sjögren's Syndrome. J Transl Int Med. 2020; 8(3):146-149. PMC: 7534498. DOI: 10.2478/jtim-2020-0023. View

Price E, Rigby S, Clancy U, Venables P . A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. J Rheumatol. 1998; 25(5):896-9. View

Tunnicliffe D, Palmer S, Henderson L, Masson P, Craig J, Tong A . Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018; 6:CD002922. PMC: 6513226. DOI: 10.1002/14651858.CD002922.pub4. View

Louvet C, Maqdasy S, Tekath M, Grobost V, Rieu V, Ruivard M . Infundibuloneurohypophysitis Associated With Sjögren Syndrome Successfully Treated With Mycophenolate Mofetil: A Case Report. Medicine (Baltimore). 2016; 95(13):e3132. PMC: 4998534. DOI: 10.1097/MD.0000000000003132. View

Ogasawara H, Sekiya M, Murashima A, Hishikawa T, Tokano Y, Sekigawa I . Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjögren's syndrome. Clin Rheumatol. 1998; 17(2):160-2. DOI: 10.1007/BF01452266. View

Pontarini E, Lucchesi D, Bombardieri M . Current views on the pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol. 2017; 30(2):215-221. DOI: 10.1097/BOR.0000000000000473. View

de Magalhaes Souza Fialho S, Bergamaschi S, Neves F, Zimmermann A, Werner de Castro G, Pereira I . Mycophenolate mofetil in primary Sjögren's syndrome: a treatment option for agranulocytosis. Rev Bras Reumatol. 2012; 52(2):297-9. View

Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M . Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2013; 74(3):526-31. DOI: 10.1136/annrheumdis-2013-203991. View

10.

Meiners P, Vissink A, Kroese F, Spijkervet F, Smitt-Kamminga N, Abdulahad W . Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014; 73(7):1393-6. DOI: 10.1136/annrheumdis-2013-204653. View

11.

Bowman S, Everett C, ODwyer J, Emery P, Pitzalis C, Ng W . Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis Rheumatol. 2017; 69(7):1440-1450. DOI: 10.1002/art.40093. View

12.

Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov B, Ene-Iordache B . Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet. 2004; 364(9433):503-12. DOI: 10.1016/S0140-6736(04)16808-6. View

13.

van Woerkom J, Kruize A, Geenen R, van Roon E, Goldschmeding R, Verstappen S . Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. Ann Rheum Dis. 2007; 66(8):1026-32. PMC: 1954693. DOI: 10.1136/ard.2006.060905. View

14.

Smedby K, Vajdic C, Falster M, Engels E, Martinez-Maza O, Turner J . Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008; 111(8):4029-38. PMC: 2288717. DOI: 10.1182/blood-2007-10-119974. View

15.

Norheim K, Harboe E, Goransson L, Omdal R . Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial. PLoS One. 2012; 7(1):e30123. PMC: 3254637. DOI: 10.1371/journal.pone.0030123. View

16.

Fox P . Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci. 2007; 1098:15-21. DOI: 10.1196/annals.1384.003. View

17.

Mackay F, Groom J, Tangye S . An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol. 2007; 19(5):406-13. DOI: 10.1097/BOR.0b013e328277ef4c. View

18.

Gottenberg J, Ravaud P, Puechal X, Le Guern V, Sibilia J, Goeb V . Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA. 2014; 312(3):249-58. DOI: 10.1001/jama.2014.7682. View

19.

Wang C, Shiang J, Huang W, Lin S . Hypokalemic paralysis as primary presentation of Fanconi syndrome associated with Sjögren syndrome. J Clin Rheumatol. 2010; 16(4):178-80. DOI: 10.1097/RHU.0b013e3181df903f. View

20.

Hahn B, McMahon M, Wilkinson A, Wallace W, Daikh D, FitzGerald J . American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012; 64(6):797-808. PMC: 3437757. DOI: 10.1002/acr.21664. View